| Literature DB >> 2910508 |
M M Bonnay1, G Recondo, A J Gouyette, J P Armand.
Abstract
The administration of a diarylsulfonylurea, LY186641, which is presently undergoing a multicentric phase I clinical trial as an anticancer agent, produces major analytical interference with commonly used creatinine analysis techniques. We confirm that this interference is caused by a metabolite rather than the parent compound and propose an alternative, interference-free method.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2910508 DOI： 10.1007/BF00273530
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333